An increase in the copy number of the SMN2 gene ameliorates the severity of SMA, and loss and compensation strongly correlate with the onset and progression of the disease5; hence, in recent years, SMN2 has become an attractive target of drug development. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.